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Abstract
Studies of rats have indicated that skeletal muscle plays a central role in whole-body nitrate ( )/nitrite (
)/nitric oxide (NO) metabolism. Extending these results to humans, however, is challenging due to the
small size of needle biopsy samples. We therefore developed a method to precisely and accurately quantify 
 and  in biopsy-sized muscle samples.  and  were extracted from rat soleus samples
using methanol combined with mechanical homogenization + ultrasound, bead beating, pulverization at
liquid N  temperature or pulverization + 0.5% Triton X-100. After centrifugation to remove proteins, 
and  were measured using HPLC. Mechanical homogenization + ultrasound resulted in the lowest 
content (62 ± 20 pmol/mg), with high variability [coefficient of variation (CV) >50%] across samples from
the same muscle. The /  ratio (0.019 ± 0.006) was also elevated, suggestive of  reduction
during tissue processing. Bead beating or pulverization yielded lower  and slightly higher  levels,
but reproducibility was still poor. Pulverization + 0.5% Triton X-100 provided the highest  content
(124 ± 12 pmol/mg) and lowest /  ratio (0.008 ± 0.001), with the least variability between duplicate
samples (CV ~15%). These values are consistent with literature data from larger rat muscle samples
analyzed using chemiluminescence. Samples were stable for at least 5 wk at −80°C, provided residual
xanthine oxidoreductase activity was blocked using 0.1 mmol/l oxypurinol. We have developed a method
capable of measuring  and  in <1 mg of muscle. This method should prove highly useful in
investigating the role of skeletal muscle in / /NO metabolism in human health and disease.
NEW & NOTEWORTHY Measurement of nitrate and especially nitrite in small, i.e., biopsy-sized, muscle
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samples is analytically challenging. We have developed a precise, accurate, and convenient method for
doing so using an affordable commercial HPLC system.
Keywords: high performance liquid chromatography, human muscle, nitrate, nitric oxide, nitrite
INTRODUCTION
Skeletal muscle has recently emerged as a central player in whole-body nitric oxide (NO) metabolism.
Specifically, studies of rodents by Piknova et al. (7, 22, 23) have demonstrated that, due in part to its mass,
muscle represents the largest reservoir of nitrate ( ) in the body. This  can potentially be reduced
intramuscularly to form nitrite ( ) and then NO via mammalian  reductases [e.g., xanthine
oxidoreductase (XOR)], thereby possibly contributing to, e.g., exercise hyperemia (22). Alternatively, 
can be exported from muscle via the circulation, thus possibly supporting NO formation in other tissues. In
turn, muscle seems to depend upon both endogenous and exogenous sources to maintain its stores of 
and . In particular, NO synthase 1-deficient mice exhibit a dramatic reduction in muscle, but not liver, 
 concentration (23), demonstrating the importance of oxidation of locally produced NO in maintaining
this pool. On the other hand, feeding rats a low /  diet for 7 days also results in a significant
reduction in the level of these compounds in muscle [and other tissues, e.g., the heart (3)], indicating that
dietary intake also normally contributes to this reservoir (7).
Given this newly appreciated importance of skeletal muscle in whole-body / /NO metabolism, at
least in rodents, it is vital to be able to perform similar measurements in humans, especially in clinical
populations that may be deficient in NO, e.g., the elderly (5, 20), patients with heart failure (29), etc. In this
context, however, the small size of human muscle biopsy samples represents an analytical challenge,
especially if other assays are also to be performed. This is particularly true for , considered the better
indicator of NO bioavailability (12, 13), as its concentration in muscle (i.e., 0.5–1 pmol/mg) is much lower
than that of  (i.e., 100–200 pmol/mg) (7, 22, 23). Laboratory reagents, glassware, etc., are also
commonly contaminated with  and  (9, 15), further compounding the issue.
Numerous methods exist for quantifying  and  in biological samples (31), several of which should
at least theoretically provide sufficient specificity and sensitivity for analysis of small amounts of human
muscle. For example, the limit of detection (LOD) of the ozone-based chemiluminescent method used by
Piknova et al. (7, 22–24) has been reported to be as low as 0.1 pmol (6). Assuming that the 
concentration of human muscle is similar to that of rodents, even 1 mg of tissue should be sufficient.
Achieving this level of sensitivity may require careful attention to experimental details, however, as the
LOD of the chemiluminescent approach is more typically stated to be ~1 pmol (18, 24, 25), requiring a
correspondingly greater amount of tissue.
Chemical ionization-gas chromatography mass spectrometry (CI-GCMS) represents another alternative for
measuring  and  in biological samples (30). As reviewed by Tsikas (31), CI-GCMS can provide
superb specificity and sensitivity, with an LOD in the femtomole range (30). A disadvantage to this
approach, however, is the high cost of the required instrumentation, i.e., 5–10 times that of a
chemiluminescent analyzer. As such, a CI-GCMS system may be beyond the reach of an individual
laboratory or investigator. Perhaps because of this, to our knowledge, this method has not been used to
measure  and  in either animal or human muscle.
HPLC can also be used to quantify  and  in blood and tissue (10).  and  may be detected
natively based on chemiluminescence, ultraviolet absorption, or electrochemical methods or after pre- or
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Mechanical homogenization plus ultrasound.
postcolumn derivatization to form compounds that are highly fluorescent or absorbent in the visible light
range. Depending upon the exact approach, the LOD has been reported to be as low as 0.05 pmol, with
methods relying upon derivatization providing the greatest sensitivity (10). HPLC systems are also
reasonably affordable, being roughly similar in cost to a chemiluminescent analyzer. However, a potential
disadvantage of HPLC in the present context is that reagents commonly used when extracting small
metabolites from muscle tissue (e.g., trichloroacetic acid) may interfere with the analysis or even damage
the HPLC system.
The purpose of the present study was to develop a method for measuring  and  in small, i.e.,
biopsy-sized, muscle samples using a commercial, turnkey HPLC system. Special attention was paid to
maximizing recovery of these metabolites from the tissue while avoiding artifactual formation of 
during sample processing or storage. Although developed for HPLC and with human muscle biopsy samples
in mind, the approach may also be useful when samples are analyzed using other methods, e.g.,
chemiluminescence or CI-GCMS, or whenever the quantity of available tissue is limited, e.g., when
studying muscle / /NO metabolism using genetically engineered mice.
METHODS
HPLC System
This study made use of a dedicated HPLC system for measuring  and  in biological samples with
a claimed LOD of 0.1 pmol, i.e., 0.01 µmol/l × 10 µl injected (ENO-30, Eicom USA, San Diego, CA). In
this system,  and  are isolated from each other and from potentially interfering substances on a
polystyrene gel separation column, the  is quantitatively converted to  on a cadmium reduction
column, and both are derivatized with Griess reagent followed by spectrophotometric detection at 540 nm.
The HPLC was calibrated before each use by manually injecting standards containing known amounts of 
 and .
Source of Tissue and Extraction Methods Tested
All study procedures were approved by the Institutional Animal Care and Use Committee at Indiana
University-Purdue University Indianapolis. Male Sprague Dawley rats weighing 300–350 g were
anesthetized with isoflurane, euthanized by exsanguination, and the soleus muscle rapidly excised, frozen in
liquid N , and stored at −80°C. The soleus, which is almost exclusively slow-twitch (1), was chosen to
minimize variability between samples because of the varying admixture of muscle fiber types. On the day of
analysis, duplicate samples were cut from the midbelly of each muscle while it was still frozen on dry ice
and processed using one of four different methods.
Per the HPLC manufacturer’s suggested guidelines, frozen
tissue samples (~50 mg; n = 4) were quickly weighed and then homogenized for 10 s in ice-cold HPLC-
grade methanol (2:1) using an Omni TH tissue homogenizer (Omni International, Kennesaw, GA) set at
maximum speed (35,000 revolutions/min). To further disrupt the tissue (3), each sample was then sonicated
for 10 × 1 s using a Fischer Model 120 Sonic Dismembrator fitted with a 1/8th inch probe (Thermo Fischer
Scientific, Waltham, MA). Tubes were immersed in an ice bath throughout processing to minimize sample
heating. Following sonication, samples were centrifuged at 10,000 g for 10 min at 4°C to remove
precipitated proteins, the supernatant was transferred to a clean (i.e., - and -free) microcentrifuge
tube, and 10 µl were injected into the HPLC.
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Bead homogenization.
Pulverization at liquid N  temperature.
Pulverization plus Triton X-100.
Bead homogenization was performed using a Bullet Blender (Next Advance, Troy,
NY). Frozen muscle samples (~50 mg; n = 6) were quickly weighed and then placed into ice-cold
microcentrifuge tubes preloaded with zirconium oxide beads, and 500 µl of ice-cold methanol were added.
Samples were then agitated for 3 min on a speed setting of 12, cooled on ice for 1 min, and this cycle
repeated a total of 10 times. After centrifugation at 10,000 g for 10 min at 4°C, the supernatant was
collected and used for  and  measurement as described above.
Frozen muscle samples (5–10 mg; n = 6) were powdered at liquid
N  temperature in a stainless steel tissue pulverizer (Bessman Tissue Pulverizer, Thermo Fischer Scientific)
using several hammer blows to the pestle. The frozen muscle powder was then transferred using a liquid N -
cooled spatula to a preweighed microcentrifuge tube containing 50 µl of ice-cold methanol. After vortexing,
samples were placed on ice for 30 min, quickly reweighed to determine the amount of tissue added, then
centrifuged and processed as described above.
Frozen muscle samples (n = 14) were processed as described immediately
above, except that 0.5% Triton X-100 was added to the methanol to help disrupt cell membranes (4).
Recovery Experiment
Recovery of  and  was determined by powdering ~100 mg of muscle and then extracting 5–10 mg
aliquots, as described above, after adding 1,250/12.5, 2,500/25, or 3,750/37.5 pmol of /  (n = 3
each) to yield final concentrations ~2×, ~3×, and ~4× normal. Percent recovery was calculated after
accounting for the contribution of endogenous  and  based on analysis of unspiked aliquots (n = 3)
of the same muscle powder.
Effect of Storage
Samples (n = 6) were processed using pulverization plus Triton X-100 as described above, and the  and
 content was measured immediately after extraction and again after 15 or 35 days of storage at −80°C.
These data were compared with those from samples (n = 8) handled identically but with the inclusion of 0.1
mmol/l of oxypurinol in the methanol/Triton X-100 extraction medium to block residual XOR activity (14,
23).
Data Analysis
Analysis of chromatograms was performed using the manufacturer’s EPC-700 Envision software. The LOD
and limit of quantification (LOQ) were calculated as 3 and 10 times, respectively, the standard error of the
estimate of the linear regression of the calibration curve (34). Statistical analyses were performed using
GraphPad Prism version 7.02 (GraphPad Software, La Jolla, CA). The effects of the extraction method on 
 content, /  ratio, and between-sample reproducibility [i.e., average coefficient of variation
(CV) for  and  content] were determined using one-way ANOVA. The effects of oxypurinol were
assessed using two-way (i.e., treatment × time) ANOVA, with time as a repeated measure. Post hoc testing
was performed using Fisher’s least-significant difference test. The within-day CV was calculated from
triplicate injections of the samples used in the recovery experiment. The between-day CV was calculated
from the data for the oxypurinol-treated samples in the long-term storage experiment. Data are presented as
mean ± SE.
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HPLC operating characteristics.
Effect of extraction method.
Recovery and reproducibility.
Effect of tissue storage.
RESULTS
The precise response factor (i.e., slope of the calibration curve) varied
somewhat (i.e., ~10%) from day to day, depending in part upon the freshness of the Griess reagent and, for 
, the age of the reduction column. However, repeated calibrations (n = 5) demonstrated high linearity
(i.e., average r = 0.9995 ± 0.0001 and 0.9996 ± 0.0001 for  and  standard curves, respectively) and
excellent sensitivity (i.e., LOD and LOQ = 0.022 ± 0.001 and 0.073 ± 0.003 pmol for  and 0.22 ± 0.01
and 0.74 ± 0.04 pmol for ). Representative standard curves for  and  are shown in Fig. 1.
Neither Triton X-100 nor oxypurinol had any acute influence on retention times, peaks shapes, or peak areas
of /  standards (data not shown), demonstrating that these reagents did not interfere with the
separation or reduction columns or with the Griess reaction. However, the use of Triton X-100 over several
days led to mild fronting of the  peak, which was reversible by cleaning the separation column per the
manufacturer’s directions.
Samples prepared via mechanical homogenization followed by ultrasound had
the lowest  content (Fig. 2, top). On the other hand, the ratio of  to  was significantly
elevated (Fig. 2, bottom), suggestive of a reduction of  to  during sample processing. There was
also large variability between paired samples from the same muscle (Table 1). Bead beating or pulverization
yielded slightly, albeit not significantly, higher  levels and a significantly lower /  ratio, but
reproducibility was still poor. Pulverization followed by extraction with methanol containing 0.5% Triton
X-100 resulted in significantly higher values for  than the other methods, with the lowest /
ratio and the least variability between duplicate samples.
Recovery of  or  added to samples processed using pulverization
plus Triton X-100 was high, whereas the CV for repeated measurements of the same sample extract was
low, both within and between days (Table 2).
The  content of tissue extracts prepared using pulverization plus Triton X-100
and stored at −80°C was stable for at least 5 wk (data not shown). However, the  content, and hence the
/  ratio, increased essentially linearly over time (Fig. 3). Addition of 0.1 mmol/l oxypurinol to the
extraction medium completely blocked this increase, obviating the need to analyze samples immediately
after processing.
A representative HPLC chromatogram from a sample prepared using the final method is shown in Fig. 4.
DISCUSSION
Recent studies by Piknova et al. (7, 22, 23) have demonstrated that, at least in rodents, skeletal muscle
serves as the body’s major /  reservoir and thus may be an important source of whole-body NO
production via the “reverse”  →  → NO pathway. Given the key role of NO in regulating
numerous physiological responses, it is critical to be able to perform similar measurements in people,
especially in clinical populations [e.g., the elderly (5, 20, 29), patients with heart failure (27), etc.] in whom
NO signaling is impaired. To date, however, there is a paucity of reliable data regarding muscle  and 
 concentrations in humans. This is especially true for , which is considered the better indicator of
NO bioavailability (12, 13). This lack of data stems from the limitations of various methods for quantifying 
 and  combined with the small amount of human muscle normally provided by the standard needle
biopsy approach.
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 and  can be measured numerous ways (31), with one particularly popular approach in recent
years being chemiluminescence (3, 6, 18, 22–25). In this method,  or  (or nitroso-containing
compounds, e.g., S-nitrosoglutathione) is reduced offline to form NO, after which the NO is reacted with
ozone in a commercial analyzer to generate a detectable photon signal. This approach provides a number of
advantages, including relatively low cost and considerable flexibility and selectivity with respect to the
chemical species being measured via careful selection of the reducing agent. Chemiluminescence has
therefore been used to measure  and  in numerous tissues (3, 14, 35), including rat skeletal muscle
(7, 22, 23). This method was also recently used by Nyakayiru et al. (19) to analyze human muscle biopsy
samples. These authors obtained values for  but reported that  was below the LOD, despite
assaying 40 mg of tissue. However, their use of strong acid (i.e., 2% perchloric acid) to deproteinize the
samples likely resulted in a significant loss of  because of its conversion to highly reactive nitrous acid
(HNO ) that then rapidly disproportionated to form NO and  (net reaction 3  + 2H  → 2NO + 
 + H O) (26). Some  might also have been lost as a result of H -mediated nitros(yl)ation of
proteins (33). The latter would seem to be especially problematic when analyzing muscle, which has a much
higher protein content than plasma or some other tissues, e.g., the brain (2). Finally, Nyakayiru et al.’s (19)
inability to detect  may also have been partially due to incomplete extraction of the tissue. This is
suggested by the fact that the basal muscle  concentration they reported was only ~60 pmol/mg, i.e.,
only one-third to one-half that of rodent muscle (7, 22, 23; present results) and only moderately higher than
that of plasma in the same subjects versus several-fold higher in rats and mice (7, 22, 23).
To avoid such issues, we developed a method to quantify the  and  concentration of biopsy-sized
samples of rat soleus muscle using a commercial HPLC system. The instrument we used relies on the Griess
reaction, i.e., the reaction of  with sulfanilamide and N-(1-naphthyl)ethylenediamine to form a highly
absorbent azo dye. This reaction is highly specific for  but is notoriously sensitive to interfering
substances (e.g., cysteine) common in biological samples (32, 33). This may explain the questionable values
for muscle  and  previously obtained by Montes de Oca et al. in patients with chronic obstructive
pulmonary disease (17) and smokers without chronic obstructive pulmonary disease (16) using a batch
(microplate) version of the Griess reaction. By first isolating  (and ) on a separation column,
however, such problems can be avoided (32). Indeed, the system we used proved to be highly stable (i.e.,
normal baseline noise = 0.0002 mV), linear, and sensitive, with a resulting LOD and LOQ for  of 0.022
and 0.073 pmol, respectively. At the same time, however, use of this HPLC system introduced additional
complications. In particular, the system is incompatible with certain reagents, including strong acids such as
those typically used to extract small metabolites from muscle. Thus, a different approach for processing the
tissue had to be employed, regardless of any concerns about acid-induced loss of  as described above.
As an alternative to strong acid, we relied on methanol to deproteinize the muscle samples, as recommended
by the HPLC manufacturer and as previously used by others when analyzing muscle samples for  and 
 using the same instrument (21). We were concerned, however, that by itself this “softer” treatment of
the tissue might not provide quantitative recovery of these ions, as has been shown for amino acids in the
presence of higher protein concentrations (27). We were also concerned about the possibility of artifactual
formation of  during sample processing because of the reduction of  by, e.g., deoxyhemoglobin or
deoxymyoglobin (22). When using the chemiluminescent method, this problem can be avoided by first
oxidizing heme groups using a potassium ferricyanide-containing “stop” solution (24), but this reagent is
also incompatible with the HPLC system. Along with the use of methanol, we tested various mechanical and
chemical methods of disrupting the tissue. Our goal was to maximize the yield of  and  and the
NO−3 NO−2
NO−3 NO−2
NO−3 NO−2
NO−3 NO−2
NO−2
2 NO−3 NO−2
+
NO−3 2 NO−2 NO−2
NO−2
NO−3
NO−3 NO−2
NO−2
NO−2
NO−3 NO−2
NO−2 NO−3
NO−2
NO−2
NO−3
NO−2
NO−2 NO−3
NO−3 NO−2
− −
Measurement of nitrate and nitrite in biopsy-sized muscle samples using HPLC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295482/?report=printable[1/6/2020 1:00:26 PM]
reproducibility of the measurements while minimizing any increase in the /  ratio.
Initially, we tried simply mechanically homogenizing samples in methanol, followed by sonication
(ultrasound) to further disrupt membranes. This method, however, resulted in low  and 
concentrations, with considerable variability between duplicate samples from the same muscle, presumably
because of inadequate disruption of the integrity of the myocytes. The ratio of  to  was also
elevated, suggesting a reduction of the latter to the former during processing, possibly because of local
heating during ultrasound treatment. These results are in line with those of Ohtake et al. (21), who found
even higher /  ratios in the gastrocnemius muscles of KKA  and C57BL/6J mice using HPLC
analysis of methanol-extracted samples.
The next methods we tried were bead homogenization and pulverization at liquid N  temperature. These
approaches seemed to slightly improve the recovery of  and  and significantly reduced the /
 ratio, but reproducibility across duplicate samples was still considered inadequate. Pulverization did,
however, permit convenient analysis of much smaller samples than mechanical or bead homogenization.
We, therefore, next tested combining pulverization with the use of a detergent (i.e., Triton X-100) to further
dissolve/disperse membranes (4). This method significantly increased the yield of  and  without
altering the /  ratio and provided better reproducibility across duplicate samples and was therefore
chosen for further evaluation.
First, we assessed the recovery of  and  from samples spiked with known amounts of these
compounds, as well as the reproducibility of measurements of the same sample extract. Recovery of 
and  in spiked samples was high, supporting the accuracy of the approach. This conclusion is
buttressed by the fact that the muscle  and  concentrations we obtained using this method are
similar to those reported by Piknova et al. (7, 22, 23) for much larger samples analyzed using their
chemiluminescent approach. These experiments also demonstrated that our final method provided results
that were precise, with both within-day and between-day CVs for both  and  of <5%. Notably,
however, this variability was much lower than that between samples from the same muscle, which averaged
14.0 ± 4.1% for the duplicate samples used to initially test the method and 11.9 ± 2.0% for the triplicate
samples used in the recovery experiment. Given the high recovery, this between-sample variability appears
to have been due to true biological variation and not the result of incomplete extraction of the tissue. As
such, these results resemble those obtained for other small muscle metabolites, e.g., lactate, when using acid
extraction (11). The physiological significance of this apparently heterogeneous distribution of  and 
 in muscle is unknown. It is notable, however, that it was observed even in a muscle, i.e., the soleus,
that is composed almost entirely of a single fiber type (1). Given fiber type-related differences in NO
synthase expression (28), etc., at least in rats, the variability in  and  content within and between
muscles of varying fiber type seems likely to be considerably larger.
Second, to determine whether deproteinization with methanol was sufficient to eliminate residual XOR
activity, we tested the effects of longer-term storage of samples at −80°C. These experiments revealed that
although the  concentration was stable over time, the  concentration, and hence the /
ratio, increased in a linear manner. This increase, however, could be completely blocked by inclusion of 0.1
mmol/l oxypurinol in the methanol/Triton X-100 extraction medium, demonstrating that it was not due to
the action of any remaining heme groups but more importantly, at least on a practical basis, eliminating the
need to extract and analyze samples on the same day.
In summary, we have developed a precise, accurate, and convenient method for extracting and measuring
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the  and  concentration of muscle samples as small as 5 mg using a commercial HPLC system.
The theoretical limit is even lower, i.e., 1 mg for both  and  or 5 ng for  alone. This method
should prove highly useful in investigating the role of human skeletal muscle in / /NO metabolism
in both healthy and diseased subject populations, in response to exercise and dietary interventions, etc. The
method should also be useful in other circumstances when the amount of tissue available is limited, e.g.,
when studying genetically engineered mice. Finally, it should be noted that although we measured  and
 using HPLC, the muscle extraction and storage method that we developed may also be useful when
the analysis is performed using a different approach, e.g., chemiluminescence or CI-GCMS. In particular,
the use of an organic solvent (i.e., methanol) plus a detergent (i.e., Triton X-100) and an XOR inhibitor (i.e.,
oxypurinol) instead of a strong acid (e.g., perchloric or trichloroacetic acid) to deproteinize, extract, and
preserve muscle samples avoids the potential loss of  that may have negatively impacted previous
results (19).
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Representative nitrite ( ) and nitrate ( ) standard curves.
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Nitrate ( ) content (top) and nitrite ( )/  ratio (bottom) of rat soleus muscles processed by mechanical
homogenization plus ultrasound (n = 4), pulverization at liquid N  temperature (n = 6), bead homogenization (n = 6), or
pulverization plus 0.5% Triton X-100 (n = 14). Data are means ± SE. Significance of differences determined by one-way
ANOVA. Homog, homogenization; Pulv, pulverization; US, ultrasound.
Table 1.
Coefficients of variation for analysis of replicate samples from the same muscle
Mechanical Homogenization +
Ultrasound
Pulverization Bead
Homogenization
Pulverization + 0.5%
Triton X-100
, % 45.7 ± 33.3 18.4 ± 12.0 9.7 ± 6.7 16.7 ± 6.0
, % 58.0 ± 23.6 51.6 ± 23.9 39.0 ± 16.0 11.3 ± 3.7
Average,
%
51.8 ± 28.4 35.0 ± 9.1 24.3 ± 10.3 14.0 ± 4.1
Values are mean ± SE for n = 4–14 samples. , nitrite; , nitrate.
Significantly different from mechanical homogenization + ultrasound or pulverization (P < 0.05),
significantly different from mechanical homogenization + ultrasound (P < 0.05).
Table 2.
Recovery and reproducibility for samples processed using pulverization plus 0.5% Triton X-100
Recovery, % 86.0 ± 3.1 96.0 ± 4.9
Within-day CV, % 3.7 ± 0.7 3.0 ± 0.4
Between-day CV, % 4.4 ± 1.0 3.5 ± 0.5
Values are mean ± SE for n = 8–12 samples. CV, coefficient of variation; , nitrite; , nitrate.
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Effect of addition of 0.1 mmol/l oxypurinol to the methanol plus 0.5% Triton X-100 extraction medium on the nitrite (
)/nitrate ( ) ratio of samples stored at −80°C for up to 5 wk. *P < 0.01 versus day 0 value for same samples. Data
are means ± SE for n = 6 samples without (w/o) oxypurinol and n = 8 for samples with (w/) oxypurinol. Significance of
differences determined by two-way (i.e., treatment × time) ANOVA, with time as a repeated measure.
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Sample HPLC chromatogram showing nitrite ( ) (inset) and nitrate ( ) peaks from 6.75 mg of rat soleus muscle
processed by pulverization at liquid N  temperature followed by extraction with 50 µl of methanol containing 0.5% Triton
X-100 and 0.1 mmol/l oxypurinol. Ten-microliter injection. Measured  content = 0.482 pmol/mg;  content = 111.1
pmol/mg.
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